EU/3/15/1533: Orphan designation for the treatment of osteogenesis imperfecta

Human allogeneic bone-marrow-derived osteoblastic cells


On 10 August 2015, orphan designation (EU/3/15/1533) was granted by the European Commission to Bone Therapeutics SA, Belgium, for human allogeneic bone-marrow-derived osteoblastic cells for the treatment of osteogenesis imperfecta.

Key facts

Active substance
Human allogeneic bone-marrow-derived osteoblastic cells
Intended use
Treatment of osteogenesis imperfecta
Orphan designation status
EU designation number
Date of designation

Rue Granbonpre 11
Brabant Wallon

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

December 2022The sponsor’s name was changed from Bone Therapeutics SA to BioSenic and the address was updated.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating